For the Inventor, By the Inventor

Enter assignee name

Los Angeles, CA, United States of America

Cytrx Corporation

USPTO Granted Patents = 28

CIPO Patents = 2

EPO Patents = 2

Trademarks = 2

Forward Citations = 438

Loading Chart...

Loading Chart...

52 inventors (with patents filed for the assignee):

R Martin Emanuele (16 out of 28 patents)

Mannarsamy Balasubramanian (9 out of 16 patents)

Robert L Hunter (9 out of 43 patents)

4. Paula H Culbreth (8 out of 8 patents)

5. László Ürögdi (7 out of 15 patents)

6. Ede Márványos (6 out of 12 patents)

7. Carlos A Rivera-Marrero (5 out of 5 patents)

8. Charles William Todd (5 out of 5 patents)

9. Robert Newton Brey, Iii (5 out of 5 patents)

10. Mark Joseph Newman (5 out of 12 patents)

11. Zita Jegesné Csákai (4 out of 4 patents)

12. Magdolna Bathóné Török (4 out of 4 patents)

13. László Dénes (4 out of 4 patents)

14. Daniel Levitt (3 out of 3 patents)

15. László Vígh (2 out of 4 patents)

28 patents: Sort by Forward Citations

1. 10881678 - Cytotoxic agents for the treatment of cancer (2021-01-05),

2. 10328093 - Anthracycline formulations (2019-06-25),

3. 10278981 - Cytotoxic agents for the treatment of cancer (2019-05-07),

4. 7745465 - Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereof (2010-06-29),

5. 7691849 - Carboxamidine derivatives and their use in the treatment of vascular diseases (2010-04-06),

6. 7550457 - Pharmaceutically effective compounds (2009-06-23),

7. 7384936 - Carboxamidine derivatives and their use in the treatment of vascular diseases (2008-06-10),

8. 7361655 - Pharmaceutically effective compounds (2008-04-22),

9. 7148239 - Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof (2006-12-12),

10. 7126002 - Pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds (2006-10-24),

11. 7045576 - Adjuvants and copolymer compositions (2006-05-16),

12. 6844001 - Adjuvants and copolymer compositions (2005-01-18),

13. RE38558 - Polyoxypropylene/polyoxyethylene copolymers with improved biological activity (2004-07-20),

14. 6747064 - Polyoxypropylene/polyoxyethylene copolymers with improved biological activity (2004-06-08),

15. 6416947 - Vaccine adjuvant and vaccine method (2002-07-09),

CytRx Corporation is a biopharmaceutical company focused on the development and commercialization of innovative cancer therapies. With a diverse pipeline of potential drug candidates, CytRx aims to revolutionize cancer treatment through targeted therapies that provide improved efficacy and reduced side effects. Through strategic partnerships and collaborations, the company is dedicated to advancing its drug candidates and making a meaningful impact in the field of oncology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

28 Patents

#60 in Los Angeles, CA

#2,767 in California

#11,610 in US

#22,565 in the World

Los Angeles, CA, United States of America

Cytrx Corporation

Forward Citations = 438

52 inventors:

R Martin Emanuele (16 out of 28 patents)

Mannarsamy Balasubramanian (9 out of 16 patents)

Robert L Hunter (9 out of 43 patents)

4. Paula H Culbreth (8 out of 8 patents)

5. László Ürögdi (7 out of 15 patents)

Please report any incorrect information to support@idiyas.com

Loading…